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OBJECTIVES: Patients with Clostridium difficileinfection (CDI) can experience long-
term symptoms that resemble a chronic disease state. Despite this, a health-related 
quality of life (HRQOL) instrument specific for patients with CDI does not exist. 
The goal of this study was to develop and validate a disease specific instrument to 
assess HRQOL in patients with CDI. METHODS: A systematic literature review was 
conducted to identify HRQOL instruments and questions related to general health 
(n= 3) or gastrointestinal disease (n= 13) related to CDI HRQOL. Removing duplicate 
questions and using direct patient (n= 10) or clinician (n= 10) interviews, a 36-item 
survey specific to CDI HRQOL was developed. Test-retest and acceptability of item 
selection was tested on 20 CDI patients and 20 healthy volunteers. The Cdiff36 
HRQOL survey was then tested using 100 patients with CDI and compared to the 
RAND Short-Form 36 (SF-36) Health Survey. Domains containing questions with a 
correlation coefficient of > 0.7 were considered acceptable. To compare population 
average scores for patients with CDI, the SF-36 was also administered to 82 patients 
given broad-spectrum antibiotics. RESULTS: SF-36 scores were significantly higher 
in healthy controls (72±22) compared to patients on broad-spectrum antibiotics 
(54±12) or patients with CDI (43±17); p< 0.05 each vs. control. The final version of 
the Cdiff36 contained six domains: daily activities (4 items), anxiety (3 items), diet 
(3 items), sleep (2 items), discomfort (6 items), health perception (6 items), dys-
phoria (6 items), relationship (2 items), and social interaction (3 items). CDiff36 
scores correlated significantly based on recurrence vs. primary CDI as well as time 
since last episode (p< 0.05, each). Cdiff36 scales also correlated significantly with the 
SF-36. CONCLUSIONS: The properties of the Cdiff36 should make it appropriate to 
assess changes over time in HRQOL in patients with CDI. Future language transla-
tions and validation will be required for global use of the CDiff36.
PGI33
SyStematIc revIew of qualItatIve StudIeS to IdentIfy HealtH 
related qualIty of lIfe conStructS rePorted by PatIentS wItH 
HePatItIS c
Mhatre S.K., Sansgiry S.S.
University of Houston, Houston, TX, USA
OBJECTIVES: The Food and Drug Administration’s (FDA) clinical trial guidelines for 
development of patient reported outcome (PRO) instruments recommends deriving 
the PRO concepts from the target population using qualitative research. Since the 
PRO instruments currently used in clinical trials of hepatitis C (HCV) patients are 
not developed specifically for this patient population, the FDA’s recommendation 
is not fulfilled. The purpose of this study was to identify a comprehensive list of 
health related quality of life (HRQoL) themes that may be unique to HCV by review-
ing qualitative studies of HCV patients. METHODS: Ovid Medline, Ovid Embase, Ovid 
PsycINFO, and PubMed were searched for peer-reviewed journals from 1946 to 2012. 
Inclusion criteria required primary studies to include HCV patients; be published 
in English; and used qualitative methods to report an aspect of the HCV experi-
ence. Studies were excluded if secondary data was used or there were proxy views. 
Included studies were graded on study quality using the Qualitative Assessment 
and Review Instrument. Eligible studies were then analyzed using meta-synthesis; 
findings from individual studies were grouped into themes which were combined to 
generate HRQoL domains. RESULTS: Ten studies met the inclusion/exclusion crite-
ria and the quality assessment criteria and were included for review. Eleven themes 
were identified: physical symptoms, physical activities, guilt, stigma, emotional 
distress, psychological behavior, social relationship, social activities, work func-
tion, sexual function, and cognitive function. The type of themes identified in each 
study varied by the focus of the primary study and the analytical framework used in 
the qualitative studies. The themes were further grouped into six HRQoL domains: 
physical, psychological/emotional, social, work, sexual, and cognitive functional-
ity. CONCLUSIONS: The systematic review represents a useful starting point in the 
critical appraisal of the PRO instruments used for clinical trials in HCV patients.
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OBJECTIVES: We assessed the impact on prescription behaviors and drug expendi-
tures of an outpatient prescription incentive program in South Korea that provides 
financial incentives to primary care physicians for less prescription of medi-
cines. METHODS: We focused on drugs for ulcer or gastro-esophageal reflux disease. 
National Health Insurance claims data for years 2009~2012 were extracted from 
1,625 clinics. A clinic-level random effects model was used. RESULTS: The overall 
impact of the program on drug expenditure was not significant. However, clinics in 
general medicine showed a lower prescription rate (-0.8 percentage points), number 
of medicines prescribed (-0.02), prescription duration (-0.15 days), and monthly 
drug expenditure (-740 won) per claim after the policy. Small clinics had lower drug 
expenditure (-650 won) and prescription duration (-0.76 days), while large clinics and 
those in group practice had higher prescription rate (+1.5 and 2.5 percentage points, 
respectively) and number of medicines prescribed (+0.03, group practice only) after 
the policy. CONCLUSIONS: The outpatient prescription incentive program worked 
as intended only in subgroups of minor clinics for the target medicines.
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self-care, or usual activities; 15.8% and 16.5% reported pain/discomfort and anxiety/
depression, respectively. The mean (standard deviation) global health score was 
83.5 (13.3) on a 0 (worst) to 100 (best) scale. Independent predictors of reporting any 
of the EQ-5D health problems included female gender, BMI 25-30 kg/m2, presence 
of comorbidity (hypertension, hyperlipidemia, etc.), family history of liver cancer, 
albumin < 28g/L, and HBeAg positive. Alcohol drinking, a diagnosis of CHB for > 15 
years, and presence of comorbidity were independent predictors of a lower global 
health score, with the effect size ranging between 1 and 4 points. CONCLUSIONS: 
CHB characteristics showed some association with patient-reported health prob-
lems, but their association with general health perception was minimal. The modest 
relationship between clinical and patient-reported outcomes measures supports 
the assessment of patient-reported outcomes in patients with CHB.
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OBJECTIVES: The impact on patient HRQoL of including ribavirin (RBV) in interferon-
free hepatitis C virus (HCV) treatment has not been determined. We assessed the 
HRQoL impact of an all-oral HCV therapy, ombitasvir/paritaprevir/ritonavir and das-
abuvir (OBV/PTV/r+DSV), with and without RBV in treatment naïve, non-cirrhotic, 
GT1a adults at the end of 12-week treatment in Phase 3 PEARL-IV trial. METHODS: 
HCV patients were randomized in a 1:2 ratio to OBV/PTV/r+DSV with RBV or OBV/
PTV/r+DSV without RBV and treated during a 12-week double-blind period. HRQoL 
was assessed using the SF-36v2 Health Survey (SF-36) which was administered 
to patients at baseline, during treatment, at end of treatment (EOT) and at post-
treatment (PT) visits. Physical Component Summary (PCS) and Mental Component 
Summary (MCS) scores were calculated for the SF-36. The statistical significance of 
differences between treatment groups in mean change from baseline to EOT was 
assessed. RESULTS: The analysis included 100 patients on OBV/PTV/r+DSV with 
RBV and 205 on OBV/PTV/r+DSV without RBV. At EOT, mean±SD decrements from 
baseline PCS and MCS scores were observed in the RBV group (change of -0.6±7.19 
in PCS and -2.9±10.55 in MCS) while small increases were observed in the non-RBV 
group (change of +0.9±7.01 in PCS and +0.3±10.09 in MCS). The difference in mean 
change from baseline to EOT did not reach statistical significance for either PCS 
(p-value= 0.105) or MCS (p-value= 0.063). At PT week 24, mean changes from baseline 
were 2.4±5.19 in PCS and 2.6±6.99 in MCS in the RBV group, and 2.2±7.00 in PCS and 
2.0±10.94 in MCS in the non-RBV group. CONCLUSIONS: At the end of 12-week 
treatment in PEARL-IV, the addition of RBV to the interferon-free all-oral OBV/PTV/
r+DSV regimen did not have a significant impact on patient HRQoL in treatment-
naïve GT1a patients. After treatment, PCS and MCS scores for both treatment groups 
showed similar improvement over baseline.
PGI31
HealtH-related qualIty of lIfe (Hrqol) In PatIentS on ombItaSvIr/ 
ParItaPrevIr /rItonavIr and daSabuvIr at tHe end of 12-week 
treatment In treatment-naÏve adultS wItH GenotyPe 1b (Gt1b) 
cHronIc HePatItIS c
Liu Y.1, Bernstein D.2, Larsen L.1, Cohen D.1, Xie Y.1, Juday T.1
1AbbVie Inc, North Chicago, IL, USA, 2North Shore University Hospital, Manhasset, IL, USA
OBJECTIVES: An all-oral HCV therapy, ombitasvir/paritaprevir/ritonavir and dasa-
buvir (OBV/PTV/r+DSV), without ribavirin (RBV), has been approved by the Food and 
Drug Administration (FDA) for treatment of treatment naïve, non-cirrhotic, GT1b 
adults. We report the HRQoL impact of OBV/PTV/r+DSV, with and without RBV, after 
12-week treatment in the Phase 3 PEARL-III trial. METHODS: HCV patients were ran-
domized in a 1:1 ratio to OBV/PTV/r+DSV with RBV or OBV/PTV/r+DSV without RBV 
and treated during a 12-week double-blind period. HRQoL was assessed using the 
SF-36 v2 Health Survey (SF-36) which was administered to patients at baseline, dur-
ing treatment, at end of treatment (EOT) and at post-treatment (PT) visits. Physical 
Component Summary (PCS) and Mental Component Summary (MCS) scores were 
calculated for the SF-36. The statistical significance of differences between treat-
ment groups in mean change from baseline to EOT was assessed. RESULTS: The 
analysis included 210 patients on OBV/PTV/r+DSV with RBV and 209 on OBV/PTV/
r+DSV without RBV. Among non-cirrhotic subjects with GT1b infection who were 
treated with OBV/PTV/r+DSV without RBV, almost no decrements from baseline 
PCS or MCS scores were observed at EOT (changes [mean±SD] of -0.1±6.71 in PCS 
and -0.1±9.09 in MCS). The decrements OBV/PTV/r+DSV with RBV were numerically 
larger (-0.5±6.80 in PCS and -1.4±9.15 in MCS); however, differences from the non-
RBV group were not statistically significant for either PCS or MCS (p-value= 0.348 
in PCS and p-value= 0.150 in MCS). At PT week 24, mean changes from baseline 
were 1.0±6.20 in PCS and 1.9±8.40 in MCS in the non-RBV group 0.9±6.04 in PCS and 
1.8±7.40 in MCS in the RBV group. CONCLUSIONS: At the end of 12-week treatment 
in PEARL-III, the interferon-free all-oral OBV/PTV/r+DSV regimen in treatment-
naïve GT1b patients had negligible impact on patient HRQoL, regardless of whether 
RBV was co-administered. After treatment, PCS and MCS scores for both treatment 
groups showed similar improvement over baseline.
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